A Humanized Monoclonal Antibody against Respiratory Syncytial Virus (Palivizumab) Inhibits RSV-Induced Neurogenic-Mediated Inflammation in Rat Airways
Open Access
- 1 March 2000
- journal article
- Published by Springer Science and Business Media LLC in Pediatric Research
- Vol. 47 (3), 351-356
- https://doi.org/10.1203/00006450-200003000-00011
Abstract
No abstract availableKeywords
This publication has 16 references indexed in Scilit:
- Respiratory syncytial virus in early life and risk of wheeze and allergy by age 13 yearsThe Lancet, 1999
- Syndrome of Periodic Fever, Aphthous stomatitis, Pharyngitis, and Adenitis (PFAPA)—What it isn’t. What is it?The Journal of Pediatrics, 1999
- Palivizumab, a Humanized Respiratory Syncytial Virus Monoclonal Antibody, Reduces Hospitalization From Respiratory Syncytial Virus Infection in High-risk InfantsPediatrics, 1998
- Replication-deficient adenoviral vector for gene transfer potentiates airway neurogenic inflammation.American Journal of Respiratory Cell and Molecular Biology, 1997
- Reduction of Respiratory Syncytial Virus Hospitalization Among Premature Infants and Infants With Bronchopulmonary Dysplasia Using Respiratory Syncytial Virus Immune Globulin ProphylaxisPediatrics, 1997
- Tachykinin Peptides, Receptors, and Peptidases in Airway DiseaseExperimental Lung Research, 1995
- Neurogenic Inflammation and AsthmaJournal of Asthma, 1992
- Glucocorticoids inhibit neurogenic plasma extravasation and prevent virus-potentiated extravasation in the rat trachea.JCI Insight, 1990
- The development of monoclonal antibodies to respiratory syncytial virus and their use in diagnosis by indirect immunofluorescenceJournal of Medical Virology, 1985
- Vascular protein leakage in various tissues induced by substance P, capsaicin, bradykinin, serotonin, histamine and by antigen challengeNaunyn-Schmiedebergs Archiv für experimentelle Pathologie und Pharmakologie, 1983